Sort
48,018 grants matching “immunotherapy”
Genomics and Computational Biology Shared Resource
$450,571Kelly A Frazer · University Of California, San Diego · P30 · FY2019 · CA
IN VITRO STUDIES OF HUMAN ANAPHYLAXIS
$450,510Johns Hopkins University · R01 · FY2004 · AI
Targeting NQO1+ tumor to trigger innate and adaptive immunity
$450,508Xiumei Huang · Indiana University Indianapolis · R01 · FY2022 · CA
Role of IL-12 family cytokines in human autoimmune Uveitis
$450,432Charles E Egwuagu · National Eye Institute · ZIA · FY2020 · EY
Development of Chimeric Antigen Receptors Targeting Multiple Myeloma
$450,431James Kochenderfer · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer
$450,429Donald W. Kufe · Dana-Farber Cancer Inst · R21 · FY2024 · CA
Canine MHC-I genotyping and tumor specific neoantigen determination
$450,417Shaying Zhao · University Of Georgia · R01 · FY2022 · CA
Host defense against poxviruses and viral immune evasion
$450,375Liang Deng · Sloan-Kettering Inst Can Research · R56 · FY2011 · AI
T cell responses to CD1-restricted lipids in tuberculosis
$450,325David Branch Moody · Brigham And Women'S Hospital · R01 · FY2025 · AI
Mechanisms by which effector T cells modulate endogenous remyelination
$450,313Peter A Calabresi · Johns Hopkins University · R37 · FY2019 · NS
Developing macrophage-based therapies for peripheral nerve injuries
$450,313Brett M. Morrison · Johns Hopkins University · R21 · FY2023 · NS
Mechanisms by which effector T cells modulate endogenous remyelination
$450,313Peter A Calabresi · Johns Hopkins University · R37 · FY2018 · NS
Development of highly neutralizing nanobodies against HIV-1, SARS-CoV-2 and other pathogens
$450,282John O'Shea · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2023 · AR
Exploiting Natural Killer cells in HIV/HBV co-infection to achieve eradication
$450,259Dimitra Peppa · University College London · R01 · FY2021 · AI
Platelet Factor 8 As A Novel Therapy for Hemophilia A
$450,252Mortimer Poncz · Children'S Hosp Of Philadelphia · P01 · FY2012 · HL
Ultrasensitive Env Detection Assay for Broadly Neutralizing Antibody Screening
$450,241Rebecca Marie Lynch · George Washington University · R61 · FY2023 · AI
Immune Mechanisms in Ocular Graft versus Host Disease
$450,227Victor L Perez · Duke University · R01 · FY2018 · EY
Interplay Between Cancer and Immune Cells on Targeted Therapy
$450,198Peter Poon-Hang Lee · Stanford University · R01 · FY2011 · CA
T Cell Immunity in Endemic Burkitt Lymphoma
$450,184Ann M Moormann · Univ Of Massachusetts Med Sch Worcester · R01 · FY2011 · CA
Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer
$450,168Dihua Yu · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Computer aided diagnosis of cancer metastases in the brain
$450,066Geoffrey Young · Brigham And Women'S Hospital · R01 · FY2020 · LM
Advancing T cell Therapy for Ovarian Cancer
$450,053George Coukos · Fox Chase Cancer Center · P50 · FY2012 · CA
Platelet Factor 8 As A Novel Therapy for Hemophilia A
$450,035Mortimer Poncz · Children'S Hosp Of Philadelphia · P01 · FY2015 · HL
Epigenetic control of Foxp3 expression in induced T regulatory cells
$450,000Anjana Rao · La Jolla Institute For Immunology · R01 · FY2019 · AI
Epigenetic control of Foxp3 expression in induced T regulatory cells
$450,000Anjana Rao · La Jolla Institute For Immunology · R01 · FY2021 · AI